Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography
Yasuyuki Komiyama
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorUtaroh Motosugi
Department or Radiology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorCorresponding Author
Shinya Maekawa
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Correspondence
Shinya Maekawa, First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi 409-3898, Japan.
Email: [email protected]
Search for more papers by this authorLeona Osawa
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorNatsuko Nakakuki
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorHitomi Takada
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMasaru Muraoka
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorYuichiro Suzuki
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMitsuaki Sato
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorShinichi Takano
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMitsuharu Fukasawa
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorTatsuya Yamaguchi
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorHiroshi Onishi
Department or Radiology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMeng Yin
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorNobuyuki Enomoto
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorYasuyuki Komiyama
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorUtaroh Motosugi
Department or Radiology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorCorresponding Author
Shinya Maekawa
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Correspondence
Shinya Maekawa, First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi 409-3898, Japan.
Email: [email protected]
Search for more papers by this authorLeona Osawa
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorNatsuko Nakakuki
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorHitomi Takada
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMasaru Muraoka
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorYuichiro Suzuki
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMitsuaki Sato
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorShinichi Takano
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMitsuharu Fukasawa
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorTatsuya Yamaguchi
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorHiroshi Onishi
Department or Radiology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorMeng Yin
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorNobuyuki Enomoto
First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan
Search for more papers by this authorAbstract
Background
The damping ratio (DR) and the loss modulus (G″) obtained by 3D MR elastography complex modulus analysis has been reported recently to reflect early intrahepatic inflammation, and is expected to be a noninvasive biomarker of inflammation in nonalcoholic fatty liver disease (NAFLD). However, the role of the DR and the G″ in Japanese NAFLD patients remains unclear.
Methods
We enrolled 39 Japanese patients with NAFLD who underwent liver biopsy and 3D MR elastography within 1 month and analyzed the association between DR, G″, and histological activity.
Results
Regarding DR, no evident correlation was observed between the DR and histological activity (p = 0.14) when patients with all fibrosis stages were included. However, when patients were restricted up to stage F2 fibrosis, the association of the DR and inflammation became significant, the DR increasing with the degree of activity (p = 0.02). Among the constituents of fibrosis activity, ballooning correlated with the DR (p < 0.01) while lobular inflammation did not. Regarding G″, it was correlated with histological activity (p < 0.01), ballooning (p < 0.01), and lobular inflammation (p < 0.01) in patients with all fibrosis stages and in patients up to F2 fibrosis (p = 0.03 for activity and p = 0.04 for ballooning). The best cutoff value of DR for hepatitis activity in patients within the F2 stage was 0.094 (area under the receiver operating characteristic curve 0.775, 95% CI: 0.529–1.000) and G″ was 0.402 (area under the receiver operating characteristic curve 0.825, 95% CI: 0.628–1.000).
Conclusions
The DR and G″ reflected the histological activity in Japanese patients with NAFLD during the early stage, indicating these values for noninvasive diagnosis of inflammation in Japanese patients with NAFLD.
CONFLICTS OF INTEREST
The Mayo Clinic and Meng Yin have intellectual property rights and a financial interest in magnetic resonance elastography technology. Other authors declare no Conflict of Interests for this article.
Supporting Information
| Filename | Description |
|---|---|
| hepr13858-sup-0001-suppl-data.pdf160.3 KB | Figures S1–S3 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(1): 73–84. https://doi.org/10.1002/hep.28431
- 2Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. Hepatol Int. 2021; 15(2): 366–79. https://doi.org/10.1007/s12072-021-10143-4
- 3Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10): 722–8. https://doi.org/10.7326/0003-4819-143-10-200511150-00009
- 4Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018; 69(4): 896–904. https://doi.org/10.1016/j.jhep.2018.05.036
- 5Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6): 1972–8. https://doi.org/10.1002/hep.23527
- 6Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014; 60(1): 110–7. https://doi.org/10.1016/j.jhep.2013.08.011
- 7Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009; 44(Suppl 19): 89–95. https://doi.org/10.1007/s00535-008-2262-x
- 8Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012; 107(2): 253–61. https://doi.org/10.1038/ajg.2011.327
- 9Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328–57. https://doi.org/10.1002/hep.29367
- 10Jang SY, Tak WY, Park SY, Kweon YO, Lee YR, Kim G, et al. Diagnostic efficacy of serum Mac-2 binding protein glycosylation isomer and other markers for liver fibrosis in non-alcoholic fatty liver diseases. Ann Lab Med. 2021; 41(3): 302–9. https://doi.org/10.3343/alm.2021.41.3.302
- 11Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, et al. Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(11): 2451–61.e3. https://doi.org/10.1016/j.cgh.2021.09.041
- 12Hoodeshenas S, Yin M, Venkatesh SK. Magnetic resonance elastography of liver: current update. Top Magn Reson Imag. 2018; 27(5): 319–33. https://doi.org/10.1097/rmr.0000000000000177
- 13Wilder J, Patel K. The clinical utility of FibroScan(®) as a noninvasive diagnostic test for liver disease. Med Devices (Auckl). 2014; 7: 107–14. https://doi.org/10.2147/mder.s46943
- 14Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007; 5(10): 1207–13.e2. https://doi.org/10.1016/j.cgh.2007.06.012
- 15Allen AM, Shah VH, Therneau TM, Venkatesh SK, Mounajjed T, Larson JJ, et al. Multiparametric magnetic resonance elastography improves the detection of NASH regression following bariatric surgery. Hepatol Commun. 2020; 4(2): 185–92. https://doi.org/10.1002/hep4.1446
- 16Allen AM, Shah VH, Therneau TM, Venkatesh SK, Mounajjed T, Larson JJ, et al. The role of three-dimensional magnetic resonance elastography in the diagnosis of nonalcoholic steatohepatitis in obese patients undergoing bariatric surgery. Hepatology. 2020; 71(2): 510–21. https://doi.org/10.1002/hep.30483
- 17Garteiser P, Pagé G, d'Assignies G, Leitao HS, Vilgrain V, Sinkus R, et al. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography. Sci Rep. 2021; 11(1):19386. https://doi.org/10.1038/s41598-021-98726-x
- 18Leitão HS, Doblas S, Garteiser P, d'Assignies G, Paradis V, Mouri F, et al. Hepatic fibrosis, inflammation, and steatosis: influence on the MR viscoelastic and diffusion parameters in patients with chronic liver disease. Radiology. 2017; 283(1): 98–107. https://doi.org/10.1148/radiol.2016151570
- 19Li J, Liu H, Mauer AS, Lucien F, Raiter A, Bandla H, et al. Characterization of cellular sources and circulating levels of extracellular vesicles in a dietary murine model of nonalcoholic steatohepatitis. Hepatol Commun. 2019; 3(9): 1235–49. https://doi.org/10.1002/hep4.1404
- 20Ma Y, Wang G, Gao F, Ma B, Song Q, Zhong S, et al. Clinical utility of 3D magnetic resonance elastography in patients with biliary obstruction. Eur Radiol. 2022; 32(3): 2050–9. https://doi.org/10.1007/s00330-021-08295-w
- 21Qu Y, Middleton MS, Loomba R, Glaser KJ, Chen J, Hooker JC, et al. Magnetic resonance elastography biomarkers for detection of histologic alterations in nonalcoholic fatty liver disease in the absence of fibrosis. Eur Radiol. 2021; 31(11): 8408–19. https://doi.org/10.1007/s00330-021-07988-6
- 22Shi Y, Qi YF, Lan GY, Wu Q, Ma B, Zhang XY, et al. Three-dimensional MR elastography depicts liver inflammation, fibrosis, and portal hypertension in chronic hepatitis B or C. Radiology. 2021; 301(1): 154–62. https://doi.org/10.1148/radiol.2021202804
- 23Yin M, Glaser KJ, Manduca A, Mounajjed T, Malhi H, Simonetto DA, et al. Distinguishing between hepatic inflammation and fibrosis with MR elastography. Radiology. 2017; 284(3): 694–705. https://doi.org/10.1148/radiol.2017160622
- 24Yin Z, Murphy MC, Li J, Glaser KJ, Mauer AS, Mounajjed T, et al. Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography. Eur Radiol. 2019; 29(11): 5823–31. https://doi.org/10.1007/s00330-019-06076-0
- 25Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: disparate associations among Asian populations. World J Hepatol. 2014; 6(5):263. https://doi.org/10.4254/wjh.v6.i5.263
- 26Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012; 55(3): 769–80. https://doi.org/10.1002/hep.24726
- 27Bonacini M, Kassamali F, Kari S, Lopez Barrera N, Kohla M. Racial differences in prevalence and severity of non-alcoholic fatty liver disease. World J Hepatol. 2021; 13(7): 763–73. https://doi.org/10.4254/wjh.v13.i7.763
- 28 E Bugianesi, E Bugianesi, eds. NASH in lean individuals. Semin Liver Dis. 2019; 39(1): 86–95. https://doi.org/10.1055/s-0038-1677517
- 29Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019; 17(4): 630–7.e8. https://doi.org/10.1016/j.cgh.2018.05.059
- 30Murphy MC, Huston J, III, Ehman RL. MR elastography of the brain and its application in neurological diseases. Neuroimage. 2019; 187: 176–83. https://doi.org/10.1016/j.neuroimage.2017.10.008
- 31Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, et al. Hepatocellular ballooning in NASH. J Hepatol. 2010; 53(4): 719–23. https://doi.org/10.1016/j.jhep.2010.04.031
- 32Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011; 458(5): 511–23. https://doi.org/10.1007/s00428-011-1066-1
- 33Kumar V, Abbas AK, Aster JC, Perkins JA, Robbins SL. Robbins basic pathology. 10th ed. Elsevier; 2018;xiv:935. https://ci.nii.ac.jp/ncid/BB23428711
- 34Li J, Allen AM, Shah VH, Manduca A, Ehman RL, Yin M. Longitudinal changes in MR elastography-based biomarkers in obese patients treated with bariatric surgery. Clin Gastroenterol Hepatol. 2021;S1542-3565(21)01146-0. https://doi.org/10.1016/j.cgh.2021.10.033
Citing Literature
